Brief: Bristol Myers Squibb Says Phase 3 Successor-2 Trial Shows MeziKd Achieves 18-Month Median PFS
BRIEF-Bristol Myers Squibb Says Phase 3 Successor-2 Trial Shows MeziKd Achieves 18-Month Median PFS May 29 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB: MEZIKD REDUCES DISEASE PROGRESSION/DEATH RISK BY OVER 50% VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
BRISTOL MYERS SQUIBB: PHASE 3 SUCCESSOR-2 TRIAL SHOWS MEZIKD ACHIEVES 18-MONTH MEDIAN PFS
BRISTOL MYERS SQUIBB: SIGNIFICANTLY IMPROVED PFS RATES WITH MEZIKD ACROSS PATIENTS IN SECOND- & THIRD-LINE AND THOSE WITH HIGHER-RISK DISEASE
BRISTOL MYERS SQUIBB: HIGHER OVERALL RESPONSE RATE AND COMPLETE RESPONSE OR BETTER WERE SEEN WITH MEZIKD
BRISTOL MYERS SQUIBB: MEDIAN OVERALL SURVIVAL WAS NOT YET REACHED WITH MEZIKD IN PHASE 3 SUCCESSOR-2 TRIAL
BRISTOL MYERS SQUIBB: SAFETY PROFILE OF MEZIKD WAS CONSISTENT WITH KNOWN PROFILE OF MEZIGDOMIDE COMBINATION REGIMEN
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC